Timber Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TMBR American 8731 https://www.timberpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Timber Pharmaceuticals Inc

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001 - Jun 5th, 2023 12:00 pm
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results - May 15th, 2023 8:15 pm
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now - Apr 14th, 2023 1:55 pm
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results - Mar 31st, 2023 8:28 pm
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology - Mar 20th, 2023 12:00 pm
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis - Feb 24th, 2023 1:00 pm
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook - Dec 14th, 2022 1:30 pm
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards - Dec 9th, 2022 9:05 pm
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results - Nov 14th, 2022 1:00 pm
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split - Nov 8th, 2022 5:10 pm
Timber Pharmaceuticals Announces Halt of Common Stock Trading - Nov 3rd, 2022 12:22 pm
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis - Oct 25th, 2022 12:00 pm
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering - Oct 3rd, 2022 1:00 pm
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis - Sep 14th, 2022 12:00 pm
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency - Aug 29th, 2022 8:05 pm
Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress - Aug 29th, 2022 12:00 pm
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - Aug 26th, 2022 12:00 pm
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results - Aug 11th, 2022 9:20 pm
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering - Aug 8th, 2022 8:05 pm
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering - Aug 4th, 2022 1:21 pm